[New substances in oncologic therapy].
After presentation of several important methodological problems in the development of new cytostatic agents, the newer substances adriamycin, the nitroso-urea derivatives, ICDT, diaminodichloro-cisplatinum, VP 16-213 and tamoxifen are briefly discussed with regard to their pharmacology and activity spectra. In this context adriamycin, diaminochloro-cisplatinum and VP 16-213 may be considered break-throughs in the field of therapeutic oncology. Finally, several newer drugs still in phase I studies are mentioned.
D000477:Alkylating Agents / Q000627:therapeutic use; D006585:Altretamine / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011929:Razoxane / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D014748:Vinca Alkaloids / Q000627:therapeutic use; D009353:Zinostatin / Q000627:therapeutic use
D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic; D009607:Nitrosourea Compounds; D014748:Vinca Alkaloids; D013629:Tamoxifen; D011929:Razoxane; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D009353:Zinostatin; D002945:Cisplatin; D006585:Altretamine
Neue Substanzen in der onkologischen Therapie.